摘要
目的:探讨采供血机构血液制品和综合医院输血常规检测病人同时进行病毒核酸筛查的必要性和可行性。方法:采集湖北省中山医院输血科2010-05-2011-05的武汉市血液中心来源血液制品3527份,以及2012-01-2012-07的输血常规检测标本中各项血清学筛查均合格的2815份血液标本作16人份混合血清样本病毒核酸扩增(NAT)检测,凡筛查不合格血样再作单人份检测。结果:HBVDNA阳性标本4例,HCVRNA和HIVRNA阳性标本未检出。结论:采用NAT技术同时筛查献血者和受血者,可以进一步有效降低输血安全风险,避免因输血传播疾病造成的医疗纠纷。
Objective：To study the necessity and feasibility of NAT testing for HBV,HCV and HIV in clinical blood transfusion. Method：3527 samples from Wuhan Blood Center from 2010 May to 2011 May and 2815 samples from Department of Clinical Laboratory,Hubei Zhongshan Hospital from 2012 January to 2012 July were collected and detected by nucleic acid amplification（NAT） testing for pools of 16 serologically negative samples,any pools positive in NAT would undergo NAT again individually. Result：HBVDNA positive specimens were found from 4 patients,HCVRNA and HIVRNA positive samples were not detected. Conclusion：Screening of blood donors and blood recipients using the technology of NAT could further reduce blood transfusion safety risk and avoid medical disputes caused by transfusion transmitted diseases.
出处
《临床血液学杂志（输血与检验）》
CAS
2013年第1期95-97,共3页
Journal of Clinical Hematology(Blood Transfusion & Laboratory Medicine)
基金
2011-2012年度湖北省卫生厅采供血管理科研项目(No:CGX2010-5)
关键词
病毒核酸扩增技术
输血安全
输血前检查
nucleic acid amplification testing
blood transfusion safety
examination before blood transfusion
作者简介
通信作者：岑千红，E-mail：cenqianhong：@163．com
